Allogene Therapeutics Inc. (NASDAQ: ALLO) reported interim results from its Phase 2 ALPHA3 trial showing 58.3% of patients achieved minimal residual disease clearance with its experimental treatment cemacabtagene ansegedleucel compared to 16.7% in the observation group.

The interim futility analysis included 24 patients with large B-cell lymphoma who had completed first-line treatment. Twelve patients received the CAR-T cell therapy while 12 were monitored without additional treatment. The 41.6 percentage point difference between groups exceeded the company's benchmark of 25-30% based on medical literature.

Plasma circulating tumor DNA levels decreased by a median of 97.7% in treated patients at day 45 compared to a 26.6% median increase in the observation group. The treatment showed no cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease.

Ten of 12 treated patients were managed entirely on an outpatient basis. Two patients required brief hospitalization for conditions unrelated to treatment. Community cancer centers accounted for approximately 33% of screening activity and treatment infusions.

The study is enrolling across more than 60 sites and expects to complete enrollment by the end of 2027. The company anticipates an interim event-free survival analysis in mid-2027 and primary analysis in mid-2028. The trial aims to enroll approximately 220 patients total.

Allogene develops allogeneic CAR-T cell therapies, which use donor cells rather than a patient's own cells for treatment. The ALPHA3 trial tests whether intervening with residual disease before clinical relapse can prevent cancer recurrence in high-risk patients.